A Game Where You Can Give Birth

The United States has funded to the tune of tens of millions of organizations promoting democracy in Egypt to the chagrin President Hosni Mubarak, according to notes obtained by Wikileaks and published Friday by the Norwegian newspaper Aftenposten .

The U.S. Agency for International Development (USAID) have planned to spend $ 66.5 million in 2008 and 75 million in 2009 to Egyptian programs on democracy and good governance, according to a note from the U.S. Embassy in Cairo from December 6, 2007.

"President Mubarak is deeply skeptical about the role of the United States in promoting democracy," said another diplomatic telegram dated 9 October 2007. "However, U.S. government programs to help establish democratic institutions and strengthen the voices of individuals in favor of a change in Egypt," added the American note. According to Aftenposten
, who said he recovered in a manner remained obscure all the diplomatic 250,000 documents obtained by Wikileaks, the United States has thus contributed directly to "develop forces that oppose the President" Mubarak.

Egypt prey to violent demonstrations

The second note indicates that the amounts paid by the United States to promote democracy covered both programs commissioned by the Egyptian government itself and financial assistance to Egyptian NGOs and American active in this field.

Egyptian Minister of International Cooperation Fayza Aboulnaga have requested in a letter to the embassy that USAID continues to fund ten of these organizations "on the ground (they) were not properly registered as an NGO," said a third note of February 28, 2008.
Generally regarded as the designated successor of President Mubarak's son Gamal is also described as "irritable on direct U.S. funding for democracy and good governance", according to a fourth note of October 20, 2008.

via lepoint.fr

Posted via email from hypha's posterous

Deep Penetration Cervix

Zelrix is a transdermal patch NUPATH designed to cure headaches. NUPATH designed this patch recently accepted by the Food and Drug Administration (FDA) for tests until 29 August 2011. This is a single-use disposable patch-based technology called transdermal iontophoretic SmartRelief. This is to deliver the sumatripan, an anti-migraine, through the skin with a mild electric charge. NUPATH ad that "This not only enables a more consistent and controlled delivery of the drug, but it also circumvents the nausea and vomiting that may occur while taking the drug orally."

Go to the end of the period of experimentation to find the first conclusions on Zelrix.

via tomsguide.fr

Posted via email from hypha's posterous

Polyps Of The Gallbladder During Pregnancy

This drug has been used in a completely different purpose.
I do not understand that we receive complaints from non-diabetic patients who took it.
they turn against their doctor has prescribed them: he was at fault

Posted via email from hypha's posterous

Why Do People Have Numbers In Their Statuses

Published Tuesday, January 25, 2011

Researchers at the Pasteur Institute, INRA, INSERM and CNRS have identified a mechanism that allows pathogenic bacteria Listeria monocytogenes to his advantage to reprogram the gene expression of the cell it infects. L. monocytogenes secretes a protein that can penetrate the nucleus of cells to take control of immune system genes of the host. This work has been published on the website of the journal Science January 20, 2011.
During infection, pathogenic bacteria must outwit the immune system of the infected host to reach a sustainable manner in their body. We knew previously that the control system of the host immune passed through the manipulation of cellular signals responsible for the activation of immune cells. A study in Listeria monocytogenes, the bacterium responsible for human listeriosis, has first to show that pathogenic bacteria can act directly in the nucleus of the host cell to their advantage to reprogram the genes under the control of interferons, intended to activate the immune system (1). The study was led by Helene Bierne within the unit cell-bacteria interactions (Institut Pasteur, Inserm Unit 604, INRA USC2020) directed by Pascale Cossart, in collaboration with other teams from the Institut Pasteur, CNRS (Gif-sur-Yvette, Université Paris Diderot - Paris 7 and Grenoble) and IBMC (Porto).
This work is in line with a study by the same team in 2009. This allowed the identification of a complex capable of locking the expression of genes in compacting the DNA (2). Here, researchers have identified a small bacterial protein, called LNTA able to blow the lock by binding directly to the complex, which causes the opening of the compacted DNA and thus access genes.
It is still unclear how and when the bacteria determines the production of this factor LNTA, but its expression is fundamental to the success of infection with Listeria, which can activate it through or suppress at will the host immunity. These studies suggest the role of epigenetic regulation - changes in gene expression that occur without altering the DNA sequence - in infection with L. monocytogenes. This discovery, if it were applied to other pathogens, provide valuable information to better understand and, ultimately, to better fight against the infectious disease and immunity.

This study received financial support including the European Community (ERANET PathoGenoMics programs and ERC).

(1) A Bacterial Protein Targets The BAHD1 Chromatin Complex to Stimulate Type III Interferon Response, Science Online, 20 January 2011
Alice Lebreton (1,2,3), Goran Lakisic (4), Viviana Job (5 ), Lauriane Fritsch (6), To Nam Tham (1,2,3), Ana Camejo (7), Jean Pierre Mattei (5), Béatrice Regnault (8), Marie-Anne Nahor (1,2,3) Didier Cabanes (7), Alexis Gautreau (4), Slimane Ait-Si-Ali (6), Andréa Dessen (5), Pascale Cossart (1,2,3) and Hélène Bierne (1.2, 3)
(1) Institut Pasteur, Bacteria Cell Interactions Unit, Paris, F -75,015 France;
(2) Inserm, U604, Paris, F-75015 France;
(3) INRA, USC2020, Paris F-75015 France.
(4) CNRS UPR3082, Laboratory of Enzymology and Structural Biochemistry, Gif-sur-Yvette, F-91198 France.
(5) Institute of Structural Biology, Bacterial Pathogenesis Group, UMR 5075 (CNRS / CEA / UJF), Grenoble, France.
(6) CNRS UMR7216, Université Paris-Diderot / Paris 7, Paris, F-75013 France.
(7) Institute for Molecular and Cell Biology, Porto, Portugal.
(8) Institut Pasteur, Génopole, Paris, F-75015 France.

(2) « Human BAHD1 promotes heterochromatic gene silencing », PNAS, 2009, vol. 106 _ no. 33 pp. 13826-13831.
Hélène Bierne, To Nam Tham, Eric Batsche, Anne Dumay, Morwenna Leguillou, Sophie Kernéis-Golsteyn, Béatrice Regnault, Jacob-S Seeler, Christian Muchardt, Jean Feunteun and Pascale Cossart.

via mypharma-editions.com

Posted via email from hypha's posterous

Repairing Polly Pocket Clothes

Comme tempers flare! As the words fly, perorations violent some officials, notwithstanding good connoisseurs of the health system, which are silent until then! Let us be lucid, France has never found a way to collaborate with health agencies its effectiveness and impartiality. The policy response to a crisis is to create each time a new structure which monitor the actions of professionals questioned and existing organizations.

Multiply the places of decision, cutting the reality in small heaps isolated each other. Each agency, each authority is composed of hundreds or thousands of staff, in offices that deal in turn records by looking first to protect themselves. Consequences: slow, fragmentation, jealousy of the chiefs and deputy chiefs, all contribute to inefficiency, under an expanded health organization on paper. Hundreds of millions of euros were injected into these machines to delay decisions on the pretext of checking cowards that hide the inefficiency of the mechanism. Why remake the world, ever publish orders, decrees and circulars which sometimes contradict each other, while Europe has already resolved the issue? Narrow nationalism generator redundancy and mismanagement.

The drug industry is made to sell boxes of pills active against disease, is it wrong? When a company has heavily bankrupt, should devote the whole profession to obloquy? Let us remember the millions who benefit daily progress of science and health products on the market. When the drug industry has left France what have we gained? A dependence of more and beatific smile of critics of the capitalist economy. The real question being put on the public square by the case of the Mediator, concerns the relationship between industry and the various health actors, doctors, experts, universities, patient groups, unions and others to political parties. To limit the spread and irresponsibility, the concentration of structures is an urgent necessity. It is urgent to fall into three areas: security, prevention and medical practice, many agencies, institutes and authorities. Thus, the cluster security meet Afssaps (Health Products), AFSSA (food safety) and Afesst (Safety); pole prevention would combine the National Institute of Health Surveillance (INVS) and the National Institute of prevention (INPS) , and the pole and colleagues in our medical practice health, the High Authority for Health (HAS) and the National Institute against Cancer (Inca). Downsizing, abolition of posts created only for good service and these duplicates so dear to the administration on the pretext of controlling the neighbor, accelerated decision circuits, performance evaluation, these are the pillars of an overhaul of our system of health protection that would reflect a real change in the polity.

The issue of experts called "independent" is meaningless, because nobody really is. The best scientists and doctors in one area are sought by all private and public. If the independent expert is not required, because its value is zero. The key will be to draw new decision circuits that prevent collusion, based on the contract and its corollary, the termination immediate and without appeal in case of conflict proved. At this price only, we will find health institutions worthy of their missions and that we really trust.

via pharmanetwork.info

Posted via email from hypha's posterous

Cost Of Xanax On Street

How do we measure life expectancy ?

Presentation

How do demographers to calculate the duration average life of a population, what is called life expectancy, so that everyone in this population are still alive and they die later?

Start animation

via ined.fr

Posted via email from hypha's posterous

Inflatable Rainbow Walker

Versatile Night 7.12.10

Jaumet Etienne (Zombie Zombie )

Lisa ( (The Big Crunch Theory)

2005 Nissan Xterra Differential Oil Plug Size

The

Tamiflu is it a panacea, a remedy against the great flu, or an invention of marketers? Against pandemics, it is no longer a government that does not recommend this drug sold by the multinational Roche.

via rue89.com

Posted via email from hypha's posterous

Pea Coat Buttons Male Or Female

The "dealer of opinion," those who sell their power influence, not recruited as among medical experts. Journalists also have a lot of ethical tightrope, this time in journalism.

With Mediator case, the public taking affine understanding of the infiltration of medical information by financial interests, including pharmaceuticals. However, a few months ago, the pathetic management of the pandemic H1N1 showed that actually pulled the strings in the French public health as well as international.

This situation is now commonplace. Until recently, the President of the powerful and wealthy French Society of Cardiology stated in the World " I'm not shocked that there is infiltration of Learned Societies by laboratories ". Unbelievable, huh?

When we pass the bounds, there is no more limits we said Alfred Jarry.

But some journalists play an important role in the disinformation oriented.

Helena Cardin health specialist on France Inter, this is a caricature of deviance. Its showpiece was a The phone rings on hormones to treat menopause. It was this treatment which helps rehabilitate yet breast cancer. She asked why the "Notables menopause [1 ] with whom she wrote a book on the subject, to extol the benefits.

via atoute.org

In practice, dealers opinion would be nothing their counterparts without "journalists." Shame on them!

Posted via email from hypha's posterous

Masterbation With A Freind

A U.S. study reveals a key to Alzheimer's disease presenting in Because the theory of overproduction of beta-amyloid plaque in the brain. Researchers directed by Dr. Randall Beteman of Washington University in St. Louis have shown that people with Alzheimer's disease can not eliminate the beta-amyloid plaque while it is produced in the same amount healthy people the same age. People with Alzheimer's disease are between 100 to 1000 times the amount of beta-amyloid in the brain than healthy people.

The researchers compared 12 people with Alzheimer's disease and 12 healthy people. The production of beta-amyloid plaque was identical in both groups but the researchers found a 30% decrease in the ability to clear beta-amyloid plaque in people with Alzheimer's disease.

A 30% decrease in the ability to clear beta-amyloid plaque means that the disease takes 10 years before patients show signs of mental impairment.

This discovery is key to the development of new treatments according to the researchers who published their findings in the renowned journal Science . By A Bless according to Science and analysis Pharmactua

via pharmactua.com

Posted via email from hypha's posterous

Eat Corn Diverticulitus

The occurrence of metastasis is a frequent event in the natural history of colonic cancer. In 20 to 30% of cases, metastases are synchronous with the discovery of the primary tumor. Furthermore, 50% of patients operated on for colonic adenocarcinoma with lymph node metastases during their evolution. Highlighting metastases in the development of colon cancer leads to systematically raise the possibility of surgical resection. In case of non-resectable metastases, the proposed treatment of chemotherapy is justified if the condition is retained. This chemotherapy was the main objective to increase the life and especially life without symptoms. The data published in a recent meta-analysis shows that the achievement of chemotherapy increases by 50% survival at 1 year without deterioration of quality of life [1]. A second goal of treatment is to enable resection of metastases. This is rare in multicenter studies [2]. The goal of treatment is usually palliative and should be clearly explained to the patient. This objective is to palliative corollary notions of chronicity (of the disease and treatment) and very high probability of death from disease progression.

The development of treatment regimens in response to a specific methodology. Drugs or drug combinations are, firstly, as assessed by clinical phase II. In these studies, the toxicity is the primary endpoint, efficiency is a secondary criterion, usually summed up by the response rate (WHO criteria). The response rate is an intermediate criterion, reproducible, confirming the effectiveness of chemotherapy on tumor disease but it can not replace the main goal of treatment is life. The Phase II study is a step of selecting treatment regimens. In a second step, the patterns of the most promising phase II are compared with the reference scheme to try to show a survival advantage. These randomized prospective studies (Phase III) or their meta-analysis have the primary endpoint of the life and the secondary criteria of life without symptoms or progression-free life. For methodological reasons, only phase III trials and meta-analysis allows the rigorous comparison of the results of survival data, toxicity and quality of life.

The recent history of chemotherapy for colon cancer has experienced two major periods. The first of 1959 to early 90's considered the only drug considered potentially effective, 5 fluorouracil (5FU) and its various methods of administration and Biomodule. This period led to the development of several schemes of "reference" in different countries and continents. The second period began with the development of new drugs (irinotecan, oxaliplatin, raltitrexed) and caused a change in the therapeutic management with the demonstration of the effectiveness of second-line treatment [3].

In the first part, tells us, using the methodological tools of evidence-based medicine (evidence-based medicine, EBM) presented in the introduction, the evolution of treatment regimens for 10 years. In

a second part, we discuss the problems of choice between different patterns.

via fmcgastro.org

Posted via email from hypha's posterous